A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity

2021 ◽  
Vol 6 (66) ◽  
Author(s):  
Murillo Silva ◽  
Yu Kato ◽  
Mariane B. Melo ◽  
Ivy Phung ◽  
Brian L. Freeman ◽  
...  
Keyword(s):  
Adaptive Immunity ◽  
Lymph Flow ◽  
Vaccine Adjuvant ◽  
Tlr Agonist

scholarly journals Surface-Engineered Cubosomes Serve as a Novel Vaccine Adjuvant to Modulate Innate Immunity and Improve Adaptive Immunity in vivo

2020 ◽  
Vol Volume 15 ◽  
pp. 8595-8608
Author(s):  
Zhenguang Liu ◽  
Lin Yu ◽  
Pengfei Gu ◽  
Ruonan Bo ◽  
Shuwen Xu ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Adaptive Immunity ◽  
Vaccine Adjuvant

scholarly journals Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 554
Author(s):  
Sören Reinke ◽  
Aneesh Thakur ◽  
Cillian Gartlan ◽  
Jelena S. Bezbradica ◽  
Anita Milicic
Keyword(s):  
Adaptive Immunity ◽  
Molecular Mechanisms ◽  
Innate Immune ◽  
Vaccine Adjuvant ◽  
Vaccine Adjuvants ◽  
Comprehensive Overview ◽  
Life Threatening ◽  
Inflammatory Caspases ◽  
The Impact ◽  
Pro Inflammatory Cytokines

In modern vaccines, adjuvants can be sophisticated immunological tools to promote robust and long-lasting protection against prevalent diseases. However, there is an urgent need to improve immunogenicity of vaccines in order to protect mankind from life-threatening diseases such as AIDS, malaria or, most recently, COVID-19. Therefore, it is important to understand the cellular and molecular mechanisms of action of vaccine adjuvants, which generally trigger the innate immune system to enhance signal transition to adaptive immunity, resulting in pathogen-specific protection. Thus, improved understanding of vaccine adjuvant mechanisms may aid in the design of “intelligent” vaccines to provide robust protection from pathogens. Various commonly used clinical adjuvants, such as aluminium salts, saponins or emulsions, have been identified as activators of inflammasomes - multiprotein signalling platforms that drive activation of inflammatory caspases, resulting in secretion of pro-inflammatory cytokines of the IL-1 family. Importantly, these cytokines affect the cellular and humoral arms of adaptive immunity, which indicates that inflammasomes represent a valuable target of vaccine adjuvants. In this review, we highlight the impact of different inflammasomes on vaccine adjuvant-induced immune responses regarding their mechanisms and immunogenicity. In this context, we focus on clinically relevant adjuvants that have been shown to activate the NLRP3 inflammasome and also present various experimental adjuvants that activate the NLRP3-, NLRC4-, AIM2-, pyrin-, or non-canonical inflammasomes and could have the potential to improve future vaccines. Together, we provide a comprehensive overview on vaccine adjuvants that are known, or suggested, to promote immunogenicity through inflammasome-mediated signalling.

A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

Vaccine ◽  
2009 ◽  
Vol 27 (34) ◽  
pp. 4662-4671 ◽  
Author(s):  
Jason Kindrachuk ◽  
Håvard Jenssen ◽  
Melissa Elliott ◽  
Rebecca Townsend ◽  
Anastasia Nijnik ◽  
...  
Keyword(s):  
Adaptive Immunity ◽  
Vaccine Adjuvant ◽  
Innate And Adaptive Immunity ◽  
Cpg Oligonucleotide ◽  
Innate Defence

Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination

Nanomedicine ◽  
2020 ◽  
Vol 15 (29) ◽  
pp. 2883-2894
Author(s):  
Saborni Chattopadhyay ◽  
Che-Ming Jack Hu
Keyword(s):  
Public Health ◽  
Adaptive Immunity ◽  
Vaccine Development ◽  
Vaccine Adjuvant ◽  
Target Cells ◽  
Innate And Adaptive Immunity ◽  
The Public ◽  
Virus Vaccination ◽  
Anticancer Immunotherapy ◽  
Cyclic Dinucleotides

The discovery of stimulator of interferon genes (STING) and their agonists as primary components that link antiviral innate and adaptive immunity has motivated growing research on STING agonist-mediated immunotherapy and vaccine development. To overcome the delivery challenge in shuttling highly polar STING agonists, typically in the form of cyclic dinucleotides, to target cells and to STING proteins in cellular cytosol, numerous nanoformulation strategies have been implemented for effective STING activation. While many STING-activating nanoparticles are developed to enhance anticancer immunotherapy, their adoption as vaccine adjuvant has vastly propelled antiviral vaccination efforts against challenging public health threats, including HIV, influenza and coronaviruses. In light of the COVID-19 pandemic that has thrusted vaccine development into the public spotlight, this review highlights advances in nanomedicinal STING agonist delivery with an emphasis on their applications in antiviral vaccination.

scholarly journals Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells

2014 ◽  
Vol 193 (4) ◽  
pp. 1920-1930 ◽  
Author(s):  
Arnaud M. Didierlaurent ◽  
Catherine Collignon ◽  
Patricia Bourguignon ◽  
Sandrine Wouters ◽  
Kaat Fierens ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Adaptive Immunity ◽  
Vaccine Adjuvant ◽  
Human Vaccine
Sign in / Sign up

Export Citation Format

Share Document